Drug intelligence / Profile preview

allisartan medoxomil + amlodipine

Development stage
Unknown
Lead developer
Daiichi Sankyo
Modality
Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Oral
01

Overview

Allisartan medoxomil + amlodipine is a fixed-dose combination antihypertensive medication containing two active ingredients: - **Allisartan medoxomil** is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle, leading to vasodilation and reduced blood pressure. - **Amlodipine** is a dihydropyridine calcium channel blocker (CCB) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, resulting in relaxation of blood vessels and further lowering of blood pressure. This combination targets two different mechanisms involved in hypertension, providing additive or synergistic effects for better control of high blood pressure. The primary indication for this drug is the treatment of hypertension (high blood pressure).

Other names
allisartan medoxomil and amlodipineallisartan + amlodipine
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on allisartan medoxomil + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on allisartan medoxomil + amlodipine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call